Aug 2026· Computational biology and chemistry· Vol 126 Pt 1, pp.
109355
· 0 citations· 38 references
Medicine
TL;DR
NGM-AML, a modular model predicting ex vivo drug response from BeatAML2 RNA-seq and sensitivity data, achieves mean Pearson and Spearman correlations of 0.324 and 0.326 across drugs, consistent with known AML survival and drug-resistance mechanisms.
Abstract
Drug response prediction in acute myeloid leukemia (AML) is challenged by sample heterogeneity and high-dimensional RNA sequencing profiles. We develop NGM-AML, a modular model predicting ex vivo drug response from BeatAML2 RNA-seq and sensitivity data. After filtering, 306 Waves 1+2 samples (28055 records) serve as training and 173 Waves 3+4 samples (16123 records) as the test set across 111 drugs. Drug targets and AML prior genes are mapped to a PPI network; random walk with restart and community detection construct 45 modules. Per drug, module scores are partitioned into sensitivity and resistance components by their association with the area under the dose-response curve. The results show that NGM-AML achieves mean Pearson and Spearman correlations of 0.324 and 0.326 across drugs, with an MAE of 37.396. Pooling all test records yields a Pearson correlation of 0.703 between predicted and observed AUC. For representative drugs, Pearson correlations reach 0.780 for Venetoclax and 0.631 for Trametinib. Within patients, median Spearman correlation and NDCG@5 are 0.75 and 0.96 for drug ranking. Runtime decreases from 87125.4 s for the raw RNA-seq model to 1102.5 s for NGM-AML. Enriched processes include extracellular matrix adhesion, integrin signaling, and RTK/MAPK pathways, consistent with known AML survival and drug-resistance mechanisms.
Results show the framework identifies sparse, interpretable, externally supported drug-sensitivity markers while enabling principled investigation of tissue-specific departures from shared effects, as well as improving sensitivity recovery under network-structured signal.
Hammed A. Olayinka, Saheed O. Olayemi· 0 citations
Acute myeloid leukemia (AML) is a molecularly heterogeneous disease, with considerable variation in molecular abnormalities and gene-expression patterns among patients. This study aimed to identify a compact diagnostic gene signature and develop an interpretable machine-learning model for distinguishing AML from normal...
Shan Liu· Theoretical and Natural Scie...· 0 citations
An AI-driven multi-omics model using GDSC, CCLE, DepMap, CTRP, and TCGA data, integrating mutation, copy-number variation, RNA expression, DNA methylation, drug SMILES, and IC50/AUC responses is developed, demonstrating that multi-omics fusion and drug-structure modeling improve prediction stability and support interpr...
Xin-Yuan Kang, Ai-Lin Deng· Applied and Computational En...· 0 citations
A quantitative model to predict intervention outcomes in a tumor using gene activation frequencies and two topological metrics: the composed coverage and the fraction of the T-network unreached by the reverse deactivation cascade (U).
Gabriel Gil, Rolando Pérez, Augusto Gonzalez· Frontiers in Systems Biology· 0 citations
TargetPrior is presented as a computational proof-of-concept for generating prioritized therapeutic hypotheses, rather than as a universal target-discovery solution, and showed stronger early-rank retrieval than network-only and statistical approaches.
This comprehensive in-silico framework integrates transcriptomic data, network analysis, pharmacophore modeling, and molecular simulations to identify novel biomarkers and drug candidates for AML, providing a foundation for further experimental validation and therapeutic development.
Partho Bosu, Tonmoy Adhikary, A. S. Rafi et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.